Pliant Therapeutics, Inc.

NASDAQ:PLRX

12.5 (USD) • At close September 18, 2024
Bedrijfsnaam Pliant Therapeutics, Inc.
Symbool PLRX
Munteenheid USD
Prijs 12.5
Beurswaarde 760,017,500
Dividendpercentage 0%
52-weken bereik 10.29 - 19.62
Industrie Biotechnology
Sector Healthcare
CEO Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.
Website https://pliantrx.com

An error occurred while fetching data.

Over Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.

Vergelijkbare Aandelen

DermTech, Inc. logo

DermTech, Inc.

DMTK

0.094 USD

Immunic, Inc. logo

Immunic, Inc.

IMUX

1.79 USD

Kronos Bio, Inc. logo

Kronos Bio, Inc.

KRON

0.92 USD

Marinus Pharmaceuticals, Inc. logo

Marinus Pharmaceuticals, Inc.

MRNS

1.51 USD

MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics

MLTX

53.11 USD

Personalis, Inc. logo

Personalis, Inc.

PSNL

5.52 USD

Sanara MedTech Inc. logo

Sanara MedTech Inc.

SMTI

31.11 USD

Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc.

LYRA

0.274 USD

Tactile Systems Technology, Inc. logo

Tactile Systems Technology, Inc.

TCMD

13.77 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)